Glucagon and GLP-1 receptor co-agonist
Mazdutide 16 mg injection once weekly
MAZD_SC_16MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -14.60 (-22.59 to -5.62) | 0.86 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 29.54 (2.16 to 606) | 0.74 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 17.83 (1.40 to 409) | 0.70 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 11.02 (0.96 to 272) | 0.66 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.43 (0.01 to 31.11) | 0.64 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 4.29 (0.34 to 137) | 0.33 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 29.40 (4.07 to 518) | 0.06 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 16.52 (2.10 to 358) | 0.18 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 15.40 (1.88 to 347) | 0.07 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.19 (0.34 to 22.39) | 0.46 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 4.22 (0.34 to 123) | 0.35 |
| Overweight or obesity without diabetes (adults) | Gallbladder and biliary disease | longest follow-up | Placebo | HR 0.44 (0.01 to 32.08) | 0.68 |